Rather than risk the patent at trial, Wyeth Pharmaceuticals went the safe route in its fight over Effexor, the company's top-selling drug and the world's best-selling anti-depressant. Wyeth agreed to lop a few years off its patent in exchange for royalties from Teva Pharmaceuticals. The FTC approved the deal because it was not considered anti-competitive, as several other big pharma/generic manufacturer deals have been of late. Unfortunately for Wyeth, three more battles over Effexor are headed to court.
Font Size: 
Wyeth's Battle for Effexor Continues
IP Law & Business
September 19, 2006
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.
